rgti stock - 10 things to know with detail
- 1. RGIT stock is the ticker symbol for Regeneron Pharmaceuticals, Inc., a biotechnology company that focuses on developing innovative medicines for serious diseases.
- 2. Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, New York.
- 3. The company is known for its flagship product Eylea, which is used to treat age-related macular degeneration and other eye diseases.
- 4. Regeneron also developed a COVID-19 treatment called REGN-COV2, which received emergency use authorization from the FDA in November 2020.
- 5. The company's stock price has experienced significant growth over the years, with a market capitalization of over $70 billion as of October 2021.
- 6. Regeneron Pharmaceuticals has a strong pipeline of experimental drugs in various stages of development, targeting a range of diseases including cancer, asthma, and arthritis.
- 7. The company has partnerships with other pharmaceutical companies, including Sanofi, to develop and commercialize new drugs.
- 8. Regeneron Pharmaceuticals has a strong track record of revenue growth, with annual revenues exceeding $8 billion in recent years.
- 9. The company has a robust research and development program, investing heavily in innovation and cutting-edge technologies to develop new treatments for unmet medical needs.
- 10. Investors interested in RGIT stock should consider the company's financial performance, pipeline of drugs, partnerships, and competition in the biotechnology industry before making investment decisions.